Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COMMENTARY
COMMENTARY
-
Present and Future of Pharmaceutical Companies in Japan -2- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
-
Present and Future of Pharmaceutical Companies in Japan -1- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
-
COMMENTARY 4 articles
December 25, 2006
-
Reform Promotion Council to Propose Reference Price System Again
December 11, 2006
-
COMMENTARY Major GE Houses Working to Increase Business with Wholesalers
November 13, 2006
-
COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
-
70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
-
Surveys by JMA, FTC Provide Evidence for Discussions on Generics
October 16, 2006
-
COMMENTARY／Original and Generic Makers Should Cooperate for Stable Supply
September 11, 2006
-
COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
-
TOPICS 2 articles
August 28, 2006
-
COMMENTARY／Government Increases Efforts to Promote Clinical Research
August 28, 2006
-
Blockbuster Sales of International Majors in 2005: Rankings of Companies and Therapeutic Areas Keiji Nakamura, Ph.D. Pharma Forum Institute, Kamakura, Japan http://www.pharma-fi.com/index.html
August 21, 2006
-
COMMENTARY 3 articles
August 7, 2006
-
5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
-
COMMENTARY：New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
-
COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
-
COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
-
Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
-
Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…